MX2018016066A - Anticuerpos anti- péptido beta amiloide n3pglu y usos de los mismos. - Google Patents
Anticuerpos anti- péptido beta amiloide n3pglu y usos de los mismos.Info
- Publication number
- MX2018016066A MX2018016066A MX2018016066A MX2018016066A MX2018016066A MX 2018016066 A MX2018016066 A MX 2018016066A MX 2018016066 A MX2018016066 A MX 2018016066A MX 2018016066 A MX2018016066 A MX 2018016066A MX 2018016066 A MX2018016066 A MX 2018016066A
- Authority
- MX
- Mexico
- Prior art keywords
- n3pglu
- amyloid beta
- beta peptide
- peptide antibodies
- n3pglu amyloid
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 2
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 238000011419 induction treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a un tratamiento de inducción a corto plazo con anticuerpos anti-Aß N3pGlu de una enfermedad caracterizada por la deposición de Aß en el cerebro, que incluye la enfermedad de Alzheimer (AD), el síndrome de Down y la angiopatía amiloide cerebral (CAA). En determinadas modalidades, a los pacientes se les administra una dosis de inducción de 10 a 60 mg/kg de un anticuerpo anti-Aß N3pGlu durante un periodo de 6 meses o menos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357579P | 2016-07-01 | 2016-07-01 | |
| PCT/US2017/038999 WO2018005282A1 (en) | 2016-07-01 | 2017-06-23 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018016066A true MX2018016066A (es) | 2019-04-24 |
Family
ID=59295341
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018016066A MX2018016066A (es) | 2016-07-01 | 2017-06-23 | Anticuerpos anti- péptido beta amiloide n3pglu y usos de los mismos. |
| MX2023001299A MX2023001299A (es) | 2016-07-01 | 2018-12-18 | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001299A MX2023001299A (es) | 2016-07-01 | 2018-12-18 | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11312763B2 (es) |
| EP (2) | EP4272828A3 (es) |
| JP (4) | JP7165588B2 (es) |
| KR (3) | KR20210024213A (es) |
| CN (3) | CN114887054A (es) |
| AU (1) | AU2017291414B2 (es) |
| BR (1) | BR112018073843A2 (es) |
| CA (1) | CA3029550C (es) |
| DK (1) | DK3478712T3 (es) |
| EA (1) | EA201892690A1 (es) |
| ES (1) | ES2958508T3 (es) |
| FI (1) | FI3478712T3 (es) |
| HR (1) | HRP20230861T1 (es) |
| HU (1) | HUE062980T2 (es) |
| IL (1) | IL263788B1 (es) |
| LT (1) | LT3478712T (es) |
| MA (1) | MA45543B1 (es) |
| MD (1) | MD3478712T2 (es) |
| MX (2) | MX2018016066A (es) |
| PL (1) | PL3478712T3 (es) |
| PT (1) | PT3478712T (es) |
| RS (1) | RS64386B1 (es) |
| SG (1) | SG11201810371XA (es) |
| SI (1) | SI3478712T1 (es) |
| TW (2) | TWI735600B (es) |
| UA (1) | UA127101C2 (es) |
| WO (1) | WO2018005282A1 (es) |
| ZA (1) | ZA201807633B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| EP3521308B1 (en) * | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
| WO2019169448A1 (en) * | 2018-03-09 | 2019-09-12 | St Vincent's Institute Of Medical Research | Multi-specific antibodies |
| CA3107370A1 (en) * | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| CN111184725B (zh) * | 2020-02-27 | 2020-12-01 | 慈溪市人民医院医疗健康集团(慈溪市人民医院) | 一种防治脑梗塞的药物制剂及其制备方法 |
| KR20230130695A (ko) * | 2021-01-11 | 2023-09-12 | 일라이 릴리 앤드 캄파니 | 항-N3pGlu 아밀로이드 베타 항체 및 그의 용도 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| AU2022376930A1 (en) * | 2021-10-29 | 2024-05-02 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| CA3236555A1 (en) * | 2021-10-29 | 2023-05-04 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| WO2023146818A2 (en) * | 2022-01-26 | 2023-08-03 | T3D Therapeutics, Inc. | Methods of treating amyloid related brain disorders using novel compounds and antibodies |
| WO2023150483A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1397539A (en) * | 1920-01-14 | 1921-11-22 | Odell Risdon Moore | Egg-carton |
| PL210157B1 (pl) | 2000-02-24 | 2011-12-30 | Lilly Co Eli | Humanizowane przeciwciało lub jego fragment, kwas polinukleinowy, wektor ekspresyjny do ekspresji przeciwciała lub jego fragmentu, komórka transfekowana wektorem ekspresyjnym, kompozycja farmaceutyczna i zastosowanie humanizowanego przeciwciała lub jego fragmentu do leczenia choroby Alzheimera |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| EP1523499A2 (en) | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| EP2298807A3 (en) | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| NO346105B1 (no) | 2005-12-12 | 2022-02-21 | E Hoffmann La Roche Ag | Antistoffer mot amyloid-beta-4 med glykosylert asparagin i den variable regionen |
| KR101413615B1 (ko) | 2006-03-23 | 2014-07-18 | 바이오악틱 뉴로사이언스 에이비 | 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도 |
| RU2498999C2 (ru) | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| LT2842967T (lt) | 2007-01-18 | 2017-02-27 | Eli Lilly And Company | Beta amiloido pegilintas fab |
| PT2182983E (pt) * | 2007-07-27 | 2014-09-01 | Janssen Alzheimer Immunotherap | Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados |
| AU2009257170B2 (en) | 2008-06-12 | 2014-06-12 | Affiris Ag | Compounds for treating symptoms associated with Parkinson's disease |
| WO2010004434A2 (en) | 2008-07-09 | 2010-01-14 | University Of Zurich | Method of promoting neurogenesis |
| MX2011000875A (es) | 2008-07-21 | 2011-04-05 | Probiodrug Ag | Ensayo de anticuerpo de diagnostico. |
| CN101397539B (zh) * | 2008-10-14 | 2011-10-05 | 中国人民解放军第三军医大学 | 组织工程组织仿生培养的模拟人体生理应力的施力装置 |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| LT3042917T (lt) | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
| WO2012021475A2 (en) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| BR112015013312A2 (pt) | 2012-12-07 | 2017-11-14 | Biogen Idec Int Neuroscience Gmbh | método para reduzir placas amiloides do cérebro usando anticorpos anti-abeta |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| AU2015213741B2 (en) | 2014-02-08 | 2020-10-08 | Genentech, Inc. | Methods of treating Alzheimer's Disease |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| WO2015191825A1 (en) * | 2014-06-13 | 2015-12-17 | Biogen Ma Inc. | Methods for the detection and measurement of amyloid beta in biological samples |
| JP6201928B2 (ja) * | 2014-08-04 | 2017-09-27 | トヨタ自動車株式会社 | 車両制御装置 |
| TWI570127B (zh) | 2014-09-15 | 2017-02-11 | 美國禮來大藥廠 | 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物 |
| TWI599358B (zh) * | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| US10017505B2 (en) | 2014-09-30 | 2018-07-10 | Merck Sharp & Dohme Corp. | Crystalline forms of a BACE inhibitor, compositions, and their use |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
-
2017
- 2017-06-16 TW TW106120115A patent/TWI735600B/zh active
- 2017-06-16 TW TW110125726A patent/TWI798751B/zh active
- 2017-06-23 EP EP23176986.0A patent/EP4272828A3/en active Pending
- 2017-06-23 MA MA45543A patent/MA45543B1/fr unknown
- 2017-06-23 CN CN202210683585.6A patent/CN114887054A/zh active Pending
- 2017-06-23 AU AU2017291414A patent/AU2017291414B2/en active Active
- 2017-06-23 SI SI201731389T patent/SI3478712T1/sl unknown
- 2017-06-23 HU HUE17736841A patent/HUE062980T2/hu unknown
- 2017-06-23 PT PT177368412T patent/PT3478712T/pt unknown
- 2017-06-23 BR BR112018073843-3A patent/BR112018073843A2/pt unknown
- 2017-06-23 ES ES17736841T patent/ES2958508T3/es active Active
- 2017-06-23 CA CA3029550A patent/CA3029550C/en active Active
- 2017-06-23 EA EA201892690A patent/EA201892690A1/ru unknown
- 2017-06-23 JP JP2018567740A patent/JP7165588B2/ja active Active
- 2017-06-23 DK DK17736841.2T patent/DK3478712T3/da active
- 2017-06-23 EP EP17736841.2A patent/EP3478712B1/en active Active
- 2017-06-23 MX MX2018016066A patent/MX2018016066A/es unknown
- 2017-06-23 LT LTEPPCT/US2017/038999T patent/LT3478712T/lt unknown
- 2017-06-23 CN CN201780040635.6A patent/CN109415433A/zh active Pending
- 2017-06-23 KR KR1020217005333A patent/KR20210024213A/ko not_active IP Right Cessation
- 2017-06-23 US US16/310,629 patent/US11312763B2/en active Active
- 2017-06-23 UA UAA201811726A patent/UA127101C2/uk unknown
- 2017-06-23 KR KR1020237004025A patent/KR20230021773A/ko not_active Application Discontinuation
- 2017-06-23 PL PL17736841.2T patent/PL3478712T3/pl unknown
- 2017-06-23 IL IL263788A patent/IL263788B1/en unknown
- 2017-06-23 HR HRP20230861TT patent/HRP20230861T1/hr unknown
- 2017-06-23 WO PCT/US2017/038999 patent/WO2018005282A1/en unknown
- 2017-06-23 KR KR1020187037757A patent/KR102221402B1/ko active IP Right Grant
- 2017-06-23 CN CN202210683554.0A patent/CN114917338A/zh active Pending
- 2017-06-23 FI FIEP17736841.2T patent/FI3478712T3/fi active
- 2017-06-23 RS RS20230595A patent/RS64386B1/sr unknown
- 2017-06-23 SG SG11201810371XA patent/SG11201810371XA/en unknown
- 2017-06-23 MD MDE20190551T patent/MD3478712T2/ro unknown
-
2018
- 2018-11-13 ZA ZA2018/07633A patent/ZA201807633B/en unknown
- 2018-12-18 MX MX2023001299A patent/MX2023001299A/es unknown
-
2020
- 2020-12-03 JP JP2020201051A patent/JP2021059547A/ja active Pending
- 2020-12-03 JP JP2020201050A patent/JP7241058B2/ja active Active
-
2022
- 2022-04-01 US US17/711,099 patent/US20220235122A1/en active Pending
-
2023
- 2023-06-06 JP JP2023093033A patent/JP2023123503A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001299A (es) | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. | |
| SA519410311B1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
| MX2018008557A (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos. | |
| MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
| MX2019007480A (es) | Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau. | |
| MA47313A (fr) | Formulations sous-cutanées d'anticorps her2 | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| PH12017500032A1 (en) | Improved a� protofibril binding antibodies | |
| MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| EA201990559A1 (ru) | Комбинированная терапия | |
| IL288636A (en) | Dosage regimen and management for the treatment or prevention of c5-related diseases using the anti-c5 antibody crobalimab | |
| EA201992284A1 (ru) | Композиции и способы лечения синуклеинопатий | |
| IL288600A (en) | Dosage regimen and management for the treatment or prevention of c5-related diseases using the anti-c5 antibody crobalimab | |
| GB201819758D0 (en) | Medicine for the treatment of Alzheimer's disease | |
| EA201892739A1 (ru) | Способы лечения болезни альцгеймера | |
| TN2019000238A1 (en) | Methods for treating complement-mediated diseases and disorders |